Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan

Shey Ying Chen, Yu Lin Lee, Yi Chun Lin, Nan Yao Lee, Chia Hung Liao, Yuan Pin Hung, Min Chi Lu, Jhong Lin Wu, Wen Pin Tseng, Chien Hao Lin, Ming Yi Chung, Chun Min Kang, Ya Fan Lee, Tai Fen Lee, Chien Yu Cheng, Cheng Pin Chen, Chien Hua Huang, Chun Eng Liu, Shu Hsing Cheng, Wen Chien KoPo Ren Hsueh, Shyr Chyr Chen

研究成果: Article同行評審

18 引文 斯高帕斯(Scopus)

摘要

This multicenter, retrospective study included 346 serum samples from 74 patients with coronavirus disease 2019 (COVID-19) and 194 serum samples from non-COVID-19 patients to evaluate the performance of five anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests, i.e. two chemiluminescence immunoassays (CLIAs): Roche Elecsys® Anti-SARS-CoV-2 Test (Roche Test) and Abbott SARS-CoV-2 IgG (Abbott Test), and three lateral flow immunoassays (LFIAs): Wondfo SARS-CoV-2 Antibody Test (Wondfo Test), ASK COVID-19 IgG/IgM Rapid Test (ASK Test), and Dynamiker 2019-nCoV IgG/IgM Rapid Test (Dynamiker Test). We found high diagnostic sensitivities (%, 95% confidence interval [CI]) for the Roche Test (97.4%, 93.4–99.0%), Abbott Test (94.0%, 89.1–96.8%), Wondfo Test (91.4%, 85.8–94.9%), ASK Test (97.4%, 93.4–99.0%), and Dynamiker Test (90.1%, 84.3–94.0%) after >21 days of symptom onset. Meanwhile, the diagnostic specificity was 99.0% (95% CI, 96.3–99.7%) for the Roche Test, 97.9% (95% CI, 94.8–99.2%) for the Abbott Test, and 100.0% (95% CI, 98.1–100.0%) for the three LFIAs. Cross-reactivity was observed in sera containing anti-cytomegalovirus (CMV) IgG/IgM antibodies and autoantibodies. No difference was observed in the time to seroconversion detection of the five serological tests. Specimens from patients with COVID-19 pneumonia demonstrated a shorter seroconversion time and higher chemiluminescent signal than those without pneumonia. Our data suggested that understanding the dynamic antibody response after COVID-19 infection and performance characteristics of different serological test are crucial for the appropriate interpretation of serological test result for the diagnosis and risk assessment of patient with COVID-19 infection.

原文English
頁(從 - 到)2157-2168
頁數12
期刊Emerging Microbes and Infections
9
發行號1
DOIs
出版狀態Published - 2020 一月 1

All Science Journal Classification (ASJC) codes

  • 寄生物學
  • 流行病學
  • 微生物學
  • 免疫學
  • 藥物發現
  • 病毒學
  • 傳染性疾病

指紋

深入研究「Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan」主題。共同形成了獨特的指紋。

引用此